Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Recruiting

Phase 3

ZilebesiranZilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Sponsor:

Alnylam Pharmaceuticals

Code:

NCT07181109

Conditions

High Risk Cardiovascular Disease

Hypertension

High Cardiovascular Risk

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zilebesiran

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-25. This information was provided to ClinicalTrials.gov by Alnylam Pharmaceuticals on 2025-10-20.